CATX (perspectivetherapeutics.com) חוב לטווח ארוך

Perspective Therapeutics specializes in developing precision alpha-therapy agents that combine radioisotopes with targeting molecules for the pinpoint destruction of tumors. Business development relies on partnerships with biotech laboratories and nuclear centers, which accelerates the launch of joint projects. The long-term liabilities figure stands at 0.00. The price trend shown below reflects the asset's dynamics amid growing demand for innovative radiopharmaceuticals.

For Perspective Therapeutics (CATX), which is scaling its targeted alpha therapy platform, long-term liabilities reflect the volume of credit resources available to fund multi-year oncology research. This metric aggregates all borrowed funds with a maturity exceeding one year, measuring the company's financial leverage. Analyzing the firm's long-term debt levels allows for an assessment of liability refinancing rates and default risk. Optimizing this indicator confirms the business's solvency during expansion into new markets.